Related Experiment Video
Updated: Apr 4, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
Jiexia Ding1, Meng Li2, Xingyong Wan2
1Department of Infectious Diseases, Hangzhou First People's Hospital, No. 261 Huansha Road, Hangzhou 310006, Zhejiang Province, China.
Abstract:
MicroRNA-34a (miR-34a) is thought to be involved in nonalcoholic fatty liver disease (NAFLD). However, the association between altered expression of miR-34a and the pathophysiological features of NAFLD remains unclear. Here, we investigated the mechanisms by which miR-34a influences NAFLD through the PPARα-related pathway. Real-time quantitative PCR, western blotting and other assays kit were used to investigate the expression and function of miR-34a in an NAFLD model. Cultured cells transfected with miR-34a inhibitor and C57BL/6 mice injected with the miR-34a inhibitor through vein tail were conducted for the effects of miR-34a on its target. MiR-34a levels were significantly upregulated in steatosis-induced hepatocytes and in liver tissues of high-fat diet-fed mice. The upregulation of miR-34a resulted in the downregulation of hepatic PPARα and SIRT1 that are the direct targets of miR-34a. Silencing miR-34a led to an initially increased expression of PPARα, SIRT1 and PPARα's downstream genes. Activation of the central metabolic sensor AMPK was also increased. The miR-34a inhibitor suppressed lipid accumulation and improved the degree of steatosis. Taken together, our data indicated that decreased expression of miR-34a potentially contributes to altered lipid metabolism in NAFLD. Downregulation of miR-34a may be a therapeutic strategy against NAFLD by regulating its target PPARα and SIRT1.
Insights
MicroRNA-34a (miR-34a) is upregulated in nonalcoholic fatty liver disease (NAFLD), downregulating PPARα and SIRT1. Silencing miR-34a reduces liver fat accumulation, suggesting miR-34a downregulation as a potential NAFLD therapy.
Area of Science:
- Molecular Biology
- Hepatology
- Metabolic Diseases
Background:
- MicroRNA-34a (miR-34a) is implicated in nonalcoholic fatty liver disease (NAFLD), but its precise role and mechanisms remain unclear.
- Understanding miR-34a's influence on NAFLD pathophysiology is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the mechanisms by which miR-34a affects NAFLD, focusing on the PPARα-related pathway.
- To determine the impact of miR-34a expression levels on hepatic lipid metabolism and NAFLD progression.
Main Methods:
- Utilized real-time quantitative PCR and western blotting to assess miR-34a expression and its targets.
- Employed cell transfection with miR-34a inhibitors and in vivo studies using C57BL/6 mice fed a high-fat diet.
- Analyzed the effects of miR-34a modulation on PPARα, SIRT1, AMPK activation, and lipid accumulation.
Main Results:
- miR-34a levels were significantly elevated in steatotic hepatocytes and high-fat diet-induced NAFLD mouse models.
- Upregulated miR-34a led to decreased expression of its direct targets, PPARα and SIRT1, and suppressed AMPK activation.
- Inhibition of miR-34a reversed these effects, reducing lipid accumulation and improving steatosis.
Conclusions:
- Decreased miR-34a expression is associated with improved lipid metabolism and reduced steatosis in NAFLD.
- Modulating miR-34a, particularly through downregulation, represents a promising therapeutic strategy for NAFLD by targeting PPARα and SIRT1 pathways.
